Literature DB >> 20394635

Outcomes of renal transplantation in recipients with Wegener's granulomatosis.

Jenny Shen1, Jagbir Gill, Muyun Shangguan, Marcelo S Sampaio, Suphamai Bunnapradist.   

Abstract

Wegener's granulomatosis (WG) is the leading cause of rapidly progressive glomerulonephritis-induced end-stage renal disease (ESRD). In this study, we compared transplant outcomes between recipients with ESRD caused by WG to recipients with ESRD secondary to other causes. Using OPTN/UNOS data from 1996 to 2007, 919 recipients with WG were identified. Post-transplant outcomes included rates of delayed graft function, acute rejection within one-yr post-transplant, overall and death-censored graft survival, and patient survival and were compared between recipients with ESRD secondary to WG versus ESRD from other causes. Recipients with ESRD because of WG had superior unadjusted and adjusted rates of graft loss, patient death, and functional graft loss (adjusted hazard ratio [HR] 0.711, 0.631, and 0.625 respectively, p < 0.001). When we compared the WG cohort to a non-WG, non-diabetic population, the HR for graft loss was still significant, but patient death and death-censored graft loss were not. Subgroup analysis of recipients aged over 60 confirmed that WG recipients had better unadjusted outcomes. This study supports the notion that renal transplantation is an effective treatment option for patients with ESRD secondary to WG. They fare similarly, if not better, than other patients.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2010        PMID: 20394635     DOI: 10.1111/j.1399-0012.2010.01248.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  8 in total

1.  Kidney Transplantation Outcomes across GN Subtypes in the United States.

Authors:  Michelle M O'Shaughnessy; Sai Liu; Maria E Montez-Rath; Colin R Lenihan; Richard A Lafayette; Wolfgang C Winkelmayer
Journal:  J Am Soc Nephrol       Date:  2016-07-18       Impact factor: 10.121

Review 2.  Kidney transplantation in ANCA-associated vasculitis.

Authors:  Michael S Sagmeister; Melissa Grigorescu; Ulf Schönermarck
Journal:  J Nephrol       Date:  2019-08-30       Impact factor: 3.902

3.  Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA.

Authors:  Michelle M O'Shaughnessy; Maria E Montez-Rath; Richard A Lafayette; Wolfgang C Winkelmayer
Journal:  Nephrol Dial Transplant       Date:  2015-11-25       Impact factor: 5.992

4.  The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand.

Authors:  Wen Tang; Bhadran Bose; Stephen P McDonald; Carmel M Hawley; Sunil V Badve; Neil Boudville; Fiona G Brown; Philip A Clayton; Scott B Campbell; Chen Au Peh; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-24       Impact factor: 8.237

5.  Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System.

Authors:  Zachary S Wallace; Rachel Wallwork; Yuqing Zhang; Na Lu; Frank Cortazar; John L Niles; Eliot Heher; John H Stone; Hyon K Choi
Journal:  Ann Rheum Dis       Date:  2018-05-14       Impact factor: 19.103

6.  Outcome of Patients With Small Vessel Vasculitis After Renal Transplantation: National Database Analysis.

Authors:  Amr El-Husseini; Sherif Saleh; Omer Hamad; Xiaonan Mei; Ana Lia Castellanos; Daniel L Davenport; Roberto Gedaly; B Peter Sawaya
Journal:  Transplant Direct       Date:  2018-02-20

7.  Outcome of kidney transplantation in pediatric patients with ANCA-associated glomerulonephritis: a single-center experience.

Authors:  Damien Noone; Rae S M Yeung; Diane Hebert
Journal:  Pediatr Nephrol       Date:  2017-08-01       Impact factor: 3.651

Review 8.  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Kidney Transplantation.

Authors:  Valentina Binda; Evaldo Favi; Marta Calatroni; Gabriella Moroni
Journal:  Medicina (Kaunas)       Date:  2021-12-03       Impact factor: 2.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.